此次通过认证的两家工厂，是公司在淄博的重要生产基地。在生产过程中，工厂积极引入先进的环保设备与工艺，持续优化生产流程，降低能源消耗与 污染物排放。为实现车间废气的高效治理与资源化利用，公司对PVC车间的原旋转式有机废气蓄热氧气炉（RTO）装置进行改造，将其替换为轮转罐VOCs 净化吸附脱附装置，该装置可显著降低废气中VOCs浓度，实现废气达标排放，同时可以大量回收有价值的高纯度回收物。 在国家"双碳"目标引领下，公司积极响应号召，将气候变化因素融入战略发展中，通过能源结构优化、生产工艺升级、资源循环利用等措施全面提升应 对气候变化能力，实现能耗与排放的"双降"。公司2024年环保投入超1.8亿元，2024年较2023年单克产品碳排放量（gCO2e）降低11%—13%，以实现经济效 益与生态效益的长期共赢。 当前，绿色制造已成为企业迈向高质量发展的重要标志。蓝帆医疗位于淄博的两家工厂成功通过淄博市绿色制造单位认证，这不仅是对蓝帆医疗在绿色发展 领域所做努力的高度认可，更是其在国际化与科技创新双轮驱动下，提升企业价值的又一有力见证。 为贯彻落实《淄博市工业领域碳达峰工作方案》要求，持续完善绿色制造体系，推进工业绿 ...

证券代码：002382 证券简称：蓝帆医疗 蓝帆医疗股份有限公司投资者关系活动记录表 编号：202501 | | □特定对象调研 □分析师会议 | | | | | | --- | --- | --- | --- | --- | --- | | 投资者关系活动 | □媒体采访 □业绩说明会 | | | | | | 类别 | □新闻发布会 □路演活动 | | | | | | | □现场参观 | | | | | | | ■其他 （2025 年山东辖区上市公司投资者网上集体接待日） | | | | | | 参与单位名称及 | 通过全景网"投资者关系互动平台"远程参与"2025 | | | | 年山东辖 | | 人员姓名 | 区上市公司投资者网上集体接待日"活动的广大投资者。 | | | | | | 时间 | 2025 5 15 (周四) 下午 15:00-16:30 | 年 | 月 | 日 | | | 地点 | 全景网"投资者关系互动平台"（https://ir.p5w.net） | | | | | | 上市公司接待人 | 董事、总裁：钟舒乔先生 副总裁、首席财务官：崔运涛先生 | | | | | | 员姓名 | | ...

Core Insights - Bluefan Medical (002382.SZ) has demonstrated strong performance through a dual strategy of "technological breakthrough + global layout," achieving significant revenue growth despite challenges in the global healthcare industry [1][5] - The company reported a revenue of 6.253 billion yuan for 2024, a year-on-year increase of 26.91%, and a net profit of 77.0223 million yuan for Q1 2025 [1][2] Business Segments - Bluefan Medical has diversified its operations into three main business segments: Cardiovascular, Health Protection, and Emergency Rescue, with a focus on high-value and low-value consumables [2][4] - The Cardiovascular segment generated over 1.1 billion yuan in sales for 2024, marking a 12% year-on-year increase, and continued to show strong growth in Q1 2025 with over 360 million yuan in sales, a 26% increase from the previous year [2][3] - The Health Protection segment saw a 33% increase in revenue, driven by new product developments and market expansion efforts [3][4] - The Emergency Rescue segment contributed stable profits, achieving approximately 30 million yuan in 2024 and 5.5 million yuan in Q1 2025, reflecting a 12% year-on-year growth [3][4] Strategic Transformation - The company has successfully transitioned from being heavily reliant on the U.S. market to a more balanced global presence, reducing its dependence on U.S. sales to below 30% of total nitrile glove exports [6][7] - Bluefan Medical has made strategic acquisitions, including the purchase of Singapore's Bosheng International and Germany's NVT, to enhance its product offerings and global reach [6][7] - The "A+X" strategy has allowed Bluefan Medical to build a complementary and risk-hedged multi-business structure, fostering innovation and new production capabilities [4][5] Market Positioning - The company has positioned itself to capitalize on opportunities arising from the U.S.-China trade tensions, with its cardiovascular business largely insulated from tariff impacts and focusing on markets in Europe, Southeast Asia, and Latin America [7] - Bluefan Medical is actively developing new products in the neurointervention and peripheral intervention sectors, with plans to accelerate market entry in response to increasing domestic demand [7]